Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Operating Expenses (2016 - 2025)

Vistagen Therapeutics' Operating Expenses history spans 13 years, with the latest figure at $19.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 29.28% year-over-year to $19.8 million; the TTM value through Dec 2025 reached $70.7 million, up 32.04%, while the annual FY2025 figure was $56.5 million, 65.64% up from the prior year.
  • Operating Expenses for Q4 2025 was $19.8 million at Vistagen Therapeutics, down from $20.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $20.3 million in Q3 2025 and bottomed at $6.7 million in Q1 2021.
  • The 4-year median for Operating Expenses is $12.2 million (2024), against an average of $12.4 million.
  • The largest annual shift saw Operating Expenses soared 262.68% in 2021 before it increased 25.3% in 2025.
  • A 4-year view of Operating Expenses shows it stood at $10.9 million in 2021, then dropped by 23.88% to $8.3 million in 2023, then surged by 85.1% to $15.4 million in 2024, then rose by 29.28% to $19.8 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Operating Expenses are $19.8 million (Q4 2025), $20.3 million (Q3 2025), and $16.0 million (Q2 2025).